{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Primary+Open-Angle+Glaucoma+%28POAG%29&page=3",
    "query": {
      "condition": "Primary Open-Angle Glaucoma (POAG)",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 155,
    "total_pages": 16,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Primary+Open-Angle+Glaucoma+%28POAG%29&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Primary+Open-Angle+Glaucoma+%28POAG%29&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-05T14:20:32.323Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07619482",
      "title": "Topical Insulin for Glaucoma (TING2)",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Open Angle Glaucoma",
        "Primary Open Angle Glaucoma",
        "Low Tension Glaucoma",
        "Pigmentary Glaucoma",
        "Pseudoexfoliation Glaucoma"
      ],
      "interventions": [
        {
          "name": "EYED-002 Low Dose (721 U/mL topical insulin)",
          "type": "DRUG"
        },
        {
          "name": "EYED-002 High Dose (1442 U/mL topical insulin)",
          "type": "DRUG"
        },
        {
          "name": "EYED-002 (highest tolerated dose, 12-month)",
          "type": "DRUG"
        },
        {
          "name": "Vehicle Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 90,
      "start_date": "2026-06",
      "completion_date": "2029-10",
      "has_results": false,
      "last_update_posted_date": "2026-06-02",
      "last_synced_at": "2026-10-05T14:20:32.323Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07619482"
    },
    {
      "nct_id": "NCT01301378",
      "title": "Patch Graft Material Safety and Effectiveness in Covering Glaucoma Drainage Device Tube",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Primary Open Angle Glaucoma",
        "Primary Angle Closure Glaucoma",
        "Pseudoexfoliation Glaucoma",
        "Pigmentary Glaucoma",
        "Traumatic Glaucoma",
        "Uveitic Glaucoma",
        "Neovascular Glaucoma"
      ],
      "interventions": [
        {
          "name": "Molteno 3 glaucoma drainage shunt",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Wills Eye",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2010-08",
      "completion_date": "2011-01",
      "has_results": false,
      "last_update_posted_date": "2016-11-22",
      "last_synced_at": "2026-10-05T14:20:32.323Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01301378"
    },
    {
      "nct_id": "NCT00515424",
      "title": "Tolerability, Safety and Efficacy of RKI983 Eye Drops in Subjects With Primary Open Angle Glaucoma and Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "RKI983",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2007-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2007-12-28",
      "last_synced_at": "2026-10-05T14:20:32.323Z",
      "location_count": 5,
      "location_summary": "Artesia, California • Rochester, New York • Charlotte, North Carolina + 2 more",
      "locations": [
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00515424"
    },
    {
      "nct_id": "NCT07390890",
      "title": "DSLT for Reducing Medication in Glaucoma",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Primary Open Angle Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "Voyager DSLT",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "The Eye Institute of West Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 60,
      "start_date": "2026-02-10",
      "completion_date": "2027-01-26",
      "has_results": false,
      "last_update_posted_date": "2026-04-20",
      "last_synced_at": "2026-10-05T14:20:32.323Z",
      "location_count": 1,
      "location_summary": "Largo, Florida",
      "locations": [
        {
          "city": "Largo",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07390890"
    },
    {
      "nct_id": "NCT03293992",
      "title": "A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7058584 Following 7 Days of Instillation of Eye Drops in Patients With Primary Open Angle Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glaucoma, Open-angle",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "0.01% RO7058584",
          "type": "DRUG"
        },
        {
          "name": "0.1% RO7058584",
          "type": "DRUG"
        },
        {
          "name": "1% RO7058584",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo",
          "type": "DRUG"
        },
        {
          "name": "Latanoprost 0.005%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 27,
      "start_date": "2017-10-10",
      "completion_date": "2017-12-21",
      "has_results": false,
      "last_update_posted_date": "2020-03-31",
      "last_synced_at": "2026-10-05T14:20:32.323Z",
      "location_count": 8,
      "location_summary": "Chandler, Arizona • Artesia, California • Inglewood, California + 5 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "Inglewood",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03293992"
    },
    {
      "nct_id": "NCT05024695",
      "title": "Evaluate the Safety and Effectiveness of iSTAR Medical's MINIject™ Implant for Lowering Intraocular Pressure (IOP) in Subjects With Primary Open-angle Glaucoma.",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Glaucoma"
      ],
      "interventions": [
        {
          "name": "MINIject™ Implant",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "iSTAR Medical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "46 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "46 Years and older"
      },
      "enrollment_count": 975,
      "start_date": "2021-08-19",
      "completion_date": "2029-07",
      "has_results": false,
      "last_update_posted_date": "2025-09-12",
      "last_synced_at": "2026-10-05T14:20:32.323Z",
      "location_count": 28,
      "location_summary": "Glendale, Arizona • Fayetteville, Arkansas • Beverly Hills, California + 24 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Chico",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05024695"
    },
    {
      "nct_id": "NCT01645319",
      "title": "Comparative Effectiveness of Treatment Strategies for Primary Open-Angle Glaucoma",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Open Angle Glaucoma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Agency for Healthcare Research and Quality (AHRQ)",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2597,
      "start_date": "2011-02",
      "completion_date": "2013-07",
      "has_results": false,
      "last_update_posted_date": "2014-01-08",
      "last_synced_at": "2026-10-05T14:20:32.323Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01645319"
    },
    {
      "nct_id": "NCT01027039",
      "title": "Will Listening to Music Make it Easier to Take a Visual Field Test?",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Glaucoma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Wills Eye",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 160,
      "start_date": "2008-06",
      "completion_date": "2009-09",
      "has_results": false,
      "last_update_posted_date": "2016-11-10",
      "last_synced_at": "2026-10-05T14:20:32.323Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01027039"
    },
    {
      "nct_id": "NCT04405245",
      "title": "Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ocular Hypertension",
        "Primary Open Angle Glaucoma"
      ],
      "interventions": [
        {
          "name": "Latanoprost ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "AKB-9778 4%",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EyePoint Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 194,
      "start_date": "2020-06-06",
      "completion_date": "2020-11-05",
      "has_results": true,
      "last_update_posted_date": "2023-05-25",
      "last_synced_at": "2026-10-05T14:20:32.323Z",
      "location_count": 21,
      "location_summary": "Inglewood, California • Mission Hills, California • Newport Beach, California + 18 more",
      "locations": [
        {
          "city": "Inglewood",
          "state": "California"
        },
        {
          "city": "Mission Hills",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Petaluma",
          "state": "California"
        },
        {
          "city": "Largo",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04405245"
    },
    {
      "nct_id": "NCT01110499",
      "title": "Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ocular Hypertension",
        "Primary Open-Angle Glaucoma"
      ],
      "interventions": [
        {
          "name": "AGN-210961 Formulation 1",
          "type": "DRUG"
        },
        {
          "name": "AGN-210961 Formulation 2",
          "type": "DRUG"
        },
        {
          "name": "AGN-210961 Formulation 3",
          "type": "DRUG"
        },
        {
          "name": "AGN-210961 Formulation 4",
          "type": "DRUG"
        },
        {
          "name": "AGN-210961 Formulation 5",
          "type": "DRUG"
        },
        {
          "name": "AGN-210961 Formulation 6",
          "type": "DRUG"
        },
        {
          "name": "AGN-210961 Formulation 7",
          "type": "DRUG"
        },
        {
          "name": "bimatoprost ophthalmic solution 0.03%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 163,
      "start_date": "2010-06",
      "completion_date": "2011-06",
      "has_results": true,
      "last_update_posted_date": "2014-08-05",
      "last_synced_at": "2026-10-05T14:20:32.323Z",
      "location_count": 1,
      "location_summary": "Newport Beach, California",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01110499"
    }
  ]
}